GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Polynovo Ltd (ASX:PNV) » Definitions » Forward PE Ratio

Polynovo (ASX:PNV) Forward PE Ratio : 147.06 (As of Jun. 06, 2024)


View and export this data going back to 1998. Start your Free Trial

What is Polynovo Forward PE Ratio?

Polynovo's Forward PE Ratio for today is 147.06.

Polynovo's PE Ratio without NRI for today is 736.67.

Polynovo's PE Ratio for today is 736.67.


Polynovo Forward PE Ratio Historical Data

The historical data trend for Polynovo's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Polynovo Forward PE Ratio Chart

Polynovo Annual Data
Trend 2020-12 2021-12 2022-04 2024-05
Forward PE Ratio
909.09 175.44 30.77 147.06

Polynovo Semi-Annual Data
2020-12 2021-03 2021-06 2021-09 2021-12 2022-03 2024-03
Forward PE Ratio 909.09 104.17 105.26 227.27 175.44 30.77 144.93

Competitive Comparison of Polynovo's Forward PE Ratio

For the Medical Devices subindustry, Polynovo's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Polynovo's Forward PE Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Polynovo's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where Polynovo's Forward PE Ratio falls into.



Polynovo Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.


Polynovo  (ASX:PNV) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .


Polynovo Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of Polynovo's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Polynovo (ASX:PNV) Business Description

Traded in Other Exchanges
Address
320 Lorimer Street, Unit 2, Port Melbourne, VIC, AUS, 3207
Polynovo earns most of its revenue from U.S. sales of its NovoSorb Biodegradable Temporizing Matrix, or NovoSorb BTM. The product is a patented biodegradable synthetic scaffold to support the regeneration of the dermis when lost through surgery, trauma, burns, or other causes of tissue loss. Once the product is applied to a wound, it takes a few weeks for the dermal layer to fully integrate within the polymer scaffold before a clinician can delaminate the outer layer. A small wound would then close either naturally or with a dressing, while a larger wound would close through a split-skin graft or alternative product such as Avita's RECELL. NovoSorb BTM then slowly degrades to harmless byproducts which are fully absorbed in roughly 18 months.

Polynovo (ASX:PNV) Headlines

No Headlines